PostEra

Name: PostEra
Brand: PostEra

Medicinal Chemistry powered by Machine Learning

Est 2019|Valuation $2.1M|Raised $28.6M

LinkedIn 5K|Website|FTEs 43|HQ Boston, Massachusetts, US

01Competitive Landscape

Narrative analysis

Where PostEra appears to offer strengths: - Synthesis-aware workflows: Manifold’s library enumeration and retrosynthesis features indicate the product is designed to align with medicinal chemistry design-make-test cycles, with awareness of chemical synthesis constraints. - Partner signals: repeated collaborations with large pharmaceutical companies and named integrations indicate market interest, though these signals are not substitutes for independent user reviews. Where alternatives may be more appropriate: - For organizations prioritizing physics-based modeling (FEP, MD, docking), Schrödinger is a commonly selected option. - For teams focused on a broad medchem analytics suite with mature multi-parameter optimization dashboards and a wide integration ecosystem, StarDrop is a mature alternative. Adoption trends / market structure: - The AI drug discovery market blends platform and pipeline models; PostEra’s communications and partnership activity place it among platform-enabled discovery providers (company social media and public communications).

	PostEra (Proton/Manifold)	Schrödinger Platform	Optibrium StarDrop
Starting Price	Not publicly listed	Not publicly listed (enterprise licensing common)	Not publicly listed (commercial licensing common)
Best suited for	Teams prioritizing synthesis-aware design and retrosynthesis combined with ML-enabled medicinal chemistry workflows; partnership-oriented engagements	Organizations requiring physics-based modeling capabilities (docking, FEP, MD) and an established enterprise computational chemistry platform	Teams seeking end-to-end design and optimization analytics with integrations for synthesis feasibility
Key Strength	Focus on synthetic accessibility (Manifold retrosynthesis, library enumeration, building-block-aware workflows); demonstrated use in open-science initiatives and pharma collaborations	Strong physics-based modeling accuracy and an established enterprise footprint in computational chemistry	Mature medchem decision-support environment with extensible integrations for synthesis feasibility
Key Weakness	Limited public transparency on enterprise security/compliance and pricing; fewer mainstream independent user reviews; mixed software vs partnership positioning	Can be resource-intensive and complex; value depends on fit and in-house expertise	Typically enterprise-licensed; synthesis planning may rely on external integrations rather than a single native stack

01Competitive Landscape

Narrative analysis

Where PostEra appears to offer strengths:

Synthesis-aware workflows: Manifold’s library enumeration and retrosynthesis features indicate the product is designed to align with medicinal chemistry design-make-test cycles, with awareness of chemical synthesis constraints.
Partner signals: repeated collaborations with large pharmaceutical companies and named integrations indicate market interest, though these signals are not substitutes for independent user reviews.

Where alternatives may be more appropriate:

For organizations prioritizing physics-based modeling (FEP, MD, docking), Schrödinger is a commonly selected option.
For teams focused on a broad medchem analytics suite with mature multi-parameter optimization dashboards and a wide integration ecosystem, StarDrop is a mature alternative.

Adoption trends / market structure:

The AI drug discovery market blends platform and pipeline models; PostEra’s communications and partnership activity place it among platform-enabled discovery providers (company social media and public communications).

	PostEra (Proton/Manifold)	Schrödinger Platform	Optibrium StarDrop
Starting Price	Not publicly listed	Not publicly listed (enterprise licensing common)	Not publicly listed (commercial licensing common)
Best suited for	Teams prioritizing synthesis-aware design and retrosynthesis combined with ML-enabled medicinal chemistry workflows; partnership-oriented engagements	Organizations requiring physics-based modeling capabilities (docking, FEP, MD) and an established enterprise computational chemistry platform	Teams seeking end-to-end design and optimization analytics with integrations for synthesis feasibility
Key Strength	Focus on synthetic accessibility (Manifold retrosynthesis, library enumeration, building-block-aware workflows); demonstrated use in open-science initiatives and pharma collaborations	Strong physics-based modeling accuracy and an established enterprise footprint in computational chemistry	Mature medchem decision-support environment with extensible integrations for synthesis feasibility
Key Weakness	Limited public transparency on enterprise security/compliance and pricing; fewer mainstream independent user reviews; mixed software vs partnership positioning	Can be resource-intensive and complex; value depends on fit and in-house expertise	Typically enterprise-licensed; synthesis planning may rely on external integrations rather than a single native stack

PostEra

01Competitive Landscape

Narrative analysis

02Market Map

01Competitive Landscape

Narrative analysis

02Market Map